TCM
BMRN icon

TimesSquare Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

TimesSquare Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-400
Closed -$22K – 244
2013
Q2 		$22K Buy
+400
New +$24.9K ﹤0.01% 243

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimesSquare Capital Management's BMRN Position: Q3 2013 in Review

TimesSquare Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2013, closing a stake of 400 shares — an estimated $22K sold.

TimesSquare Capital Management first reported a position in BMRN in Q2 2013 and held it in 1 quarter. The position peaked at $22K in Q2 2013. 294 funds tracked by Wall St. Rank hold BMRN as of Q3 2013.

  • TimesSquare Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • TimesSquare Capital Management sold 400 BioMarin Pharmaceuticals shares in Q3 2013, an estimated $22K.
  • TimesSquare Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • TimesSquare Capital Management's BioMarin Pharmaceuticals position peaked at $22K in Q2 2013.
  • 294 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2013.

Based on TimesSquare Capital Management's 13F filing for Q3 2013, filed 12 Nov 2013.